2024 American Academy of Neurology Abstract Website

Disclosures for "Assessing the Clinical and Treatment Landscape of Genetic Epilepsies Through 3,760 Individuals"

Miss Xian has nothing to disclose.
Mr. Kaufman has nothing to disclose.
The institution of Mrs. Ruggiero has received research support from STXBP1 Disorders Foundation.
Mr. Ramos has nothing to disclose.
Mr. Gonzalez has nothing to disclose.
Ms. Back has nothing to disclose.
Ms. Bailey-Medley has nothing to disclose.
Ms. Cohen has nothing to disclose.
The institution of Dr. Cuddapah has received research support from NIH. The institution of Dr. Cuddapah has received research support from CURE Epilepsy.
Dr. Ellis has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Epiminder.
Ms. Ginn has nothing to disclose.
Dr. Lewin has nothing to disclose.
The institution of Miss Lusk has received research support from NIH. The institution of Miss Lusk has received research support from CACNA1A Foundation.
Dr. Marsh has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Acadia Pharmacuticals. Dr. Marsh has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Stoke Therapeutics. Dr. Marsh has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Acadia Pharmaceuticals. The institution of Dr. Marsh has received research support from NIH. The institution of Dr. Marsh has received research support from Rett Syndrome Research Trust. The institution of Dr. Marsh has received research support from International Rett Syndrome Foundation. The institution of Dr. Marsh has received research support from Eagles Autism Challenge. The institution of Dr. Marsh has received research support from LouLou Foundation. The institution of Dr. Marsh has received research support from International CDKL5 Resarch Foundation. The institution of Dr. Marsh has received research support from Acadia Pharmaceuticals. The institution of Dr. Marsh has received research support from Marinus. The institution of Dr. Marsh has received research support from Stoke Therapeutics. The institution of Dr. Marsh has received research support from Takeda Pharmaceuticals. Dr. Marsh has received personal compensation in the range of $500-$4,999 for serving as a Grant Review with NIH. Dr. Marsh has received personal compensation in the range of $5,000-$9,999 for serving as a Expert Witness with Department of Human Services. Dr. Marsh has received personal compensation in the range of $500-$4,999 for serving as a Speaker with Medscape.
Dr. Massey has a non-compensated relationship as a consultant with Sun Pharmaceutical Ltd that is relevant to AAN interests or activities.
The institution of Dr. Ortiz-Gonzalez has received research support from Robert Wood Johnson Foundation . The institution of Dr. Ortiz-Gonzalez has received research support from NINDS.
Dr. Pojomovsky McDonnell has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Connected Research. Dr. Pojomovsky McDonnell has received research support from AAN.
Ms. Sullivan has nothing to disclose.
Dr. Taub has nothing to disclose.
Ms. Tefft has nothing to disclose.
Ms. Helbig has nothing to disclose.
Dr. Goldberg has nothing to disclose.
Dr. Helbig has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Encoded. Dr. Helbig has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Capsida. Dr. Helbig has received intellectual property interests from a discovery or technology relating to health care.
Dr. Fitzgerald has nothing to disclose.